Our mission:
CGM coverage for all. 

Continuous glucose monitoring with Dexcom has been proven to help people with diabetes spend more time in range and lower A1C.1-5 But tens of millions of Americans still lack coverage for CGM. Dexcom is on a mission to change that – empowering all people with diabetes to take control of their health.  
  • Get Notified As Coverage Expands
Track Our Progress
Select a state to view CGM coverage in that area.6

Insurance Coverage

0-25%

25-50%

51-75%

76-99%

100%

Insurance Type

Treatment Type

*Coverage map reflects statewide averages for all private and government coverage. Individual coverage may vary.
†Medicare covers CGM for 100% of people with diabetes that use any type of insulin or experience low glucose events.
The Road to 100
Explore key milestones along our journey to 100% coverage for CGM.

Coverage has come a long way since the earliest days of CGM technology. Driven by innovation and clinical evidence, Dexcom has helped push coverage forward, but the journey isn’t over yet. 
See how far we’ve come, and why the mission continues.  

How Dexcom fights for coverage

Clinical evidence

Dexcom supports clinical trials and real-world studies to demonstrate how CGM improves outcomes for people with diabetes. We share this evidence through scientific publications and leading medical conferences, helping support value, broader coverage, and access to CGM.

Policy engagement

We engage with policymakers and regulatory agencies to advance coverage policies for CGM. By sharing evidence, insights, and user perspectives, we help remove barriers, expand access and normalize CGM as the default standard of care for all people with diabetes.

Collaboration with insurers

Dexcom works with payors to improve coverage and access to CGM. Through ongoing collaboration, we share clinical evidence, real-world data, and future innovations to demonstrate how CGM improves outcomes, supports quality care, and reduces long-term healthcare costs. 

Get Involved

Want to stand up for CGM coverage and help people with diabetes? Use your voice on social media to share information, personal stories, or coverage updates, and help spread awareness about the importance of CGM access.  
Also, consider getting involved with one of the many trusted organizations that advocate for the needs of the diabetes community.

Stay in Touch

*Coverage map reflects statewide averages for all private and government coverage. Individual coverage may vary. Medicare covers CGM for 100% of people with diabetes that use any type of insulin or experience low glucose events. Fingersticks required for diabetes treatment decisions if symptoms or expectations do not match readings.
1 Beck, RW, et al. JAMA. 2017;317(4):371-378.
2 Beck RW, et al. Ann Intern Med. 2017;167(6):365-374.
3 Martens T, et al. JAMA. 2021;325(22):2262-2272.
4 Garg SK, et al. Diabetes Technol Ther. 2025;27(6):413-502.
5 Welsh JB, et al. J Diabetes Sci Technol. 2024;18(1):143-7.
6 Dexcom, Data on File, 2026.
7 Centers for Medicare & Medicaid Services. ˝Article - Glucose Monitor - Policy Article (A52464).˛ www.cms.gov, 18 Feb. 2025.
BRIEF SAFETY STATEMENT: Failure to use the Dexcom Continuous Glucose Monitoring System and its components according to the instructions for use provided with your device and available at (https://www.dexcom.com/safety-information and to properly consider all indications, contraindications, warnings, precautions, and cautions in those instructions for use may result in you missing a severe hypoglycemia (low blood glucose) or hyperglycemia (high blood glucose) occurrence and/or making a treatment decision that may result in injury. If your glucose alerts and readings from the Dexcom CGM do not match symptoms, use a blood glucose meter to make diabetes treatment decisions. Seek medical advice and attention when appropriate, including for any medical emergency.

Dexcom, Dexcom Clarity, Dexcom Follow, Dexcom One, Dexcom Share, Stelo, and any related logos and design marks are either registered trademarks or trademarks of Dexcom, Inc. in the United States and/or other countries. MAT-13884